AVBP in “China Becomes Pharma's Global R&D Engine”
ArriVent BioPharma, Inc.
ArriVent’s lead asset furmonertinib was licensed from China’s Allist and uses extensive Chinese clinical evidence as the foundation for global development.
AVBP impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to AVBP’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading AVBP impact map…
Price history, marked with story events
Aug 27, 2025 – Aug 28, 2026 · 247 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — ArriVent’s lead asset furmonertinib was licensed from China’s Allist and uses extensive Chinese clinical evidence as the foundation for global development.
Read the full China Becomes Pharma's Global R&D Engine story